within Pharmacolibrary.Drugs.ATC.N;

model N07XX07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 350 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,
    adminCount     = 1,
    Vd             = 0.0026,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Fampridine (also known as 4-aminopyridine, dalfampridine) is a potassium channel blocker used to improve walking in adults with multiple sclerosis (MS). It is approved and marketed for symptomatic treatment in MS patients to enhance walking speed.</p><h4>Pharmacokinetics</h4><p>Single-dose pharmacokinetic study in healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Hayes, KC, et al., &amp; Cohen, R (2004). Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (Fampridine-SR) in subjects with chronic, incomplete spinal cord injury. <i>Archives of physical medicine and rehabilitation</i> 85(1) 29–34. DOI:<a href=&quot;https://doi.org/10.1016/s0003-9993(03)00651-8&quot;>10.1016/s0003-9993(03)00651-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14970964/&quot;>https://pubmed.ncbi.nlm.nih.gov/14970964</a></p></li><li><p>Blight, AR, &amp; Henney, HR (2009). Pharmacokinetics of 14C-radioactivity after oral intake of a single dose of 14C-labeled fampridine (4-aminopyridine) in healthy volunteers. <i>Clinical therapeutics</i> 31(2) 328–335. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.02.004&quot;>10.1016/j.clinthera.2009.02.004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19302905/&quot;>https://pubmed.ncbi.nlm.nih.gov/19302905</a></p></li><li><p>Vollmer, T, et al., &amp; Henney, HR (2009). Steady-state pharmacokinetics and tolerability of orally administered fampridine sustained-release 10-mg tablets in patients with multiple sclerosis: a 2-week, open-label, follow-up study. <i>Clinical therapeutics</i> 31(10) 2215–2223. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2009.10.007&quot;>10.1016/j.clinthera.2009.10.007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/19922892/&quot;>https://pubmed.ncbi.nlm.nih.gov/19922892</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end N07XX07;
